Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction

被引:15
作者
Wang, Norman C. [2 ]
Piccini, Jonathan P. [3 ]
Konstam, Marvin A. [4 ]
Maggioni, Aldo P. [5 ]
Traver, Brian [6 ]
Swedberg, Karl [7 ]
Udelson, James E. [4 ]
Zannad, Faiez [8 ]
Cook, Thomas [6 ]
O'Connor, Christopher M. [10 ]
Miller, Alan B. [9 ]
Grinfeld, Liliana [11 ]
Gheorghiade, Mihai [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Duke Clin Res Inst, Durham, NC USA
[4] Tufts Med Ctr, Boston, MA USA
[5] ANMCO Res Ctr, Florence, Italy
[6] Univ Wisconsin, Madison, WI USA
[7] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden
[8] CHU, INSERM, U961, Nancy, France
[9] Univ Florida, Jacksonville, FL USA
[10] Duke Univ, Durham, NC USA
[11] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
关键词
heart failure; hospitalization; sudden death; implantable cardioverter-defibrillator; outcomes; VASOPRESSIN ANTAGONISM; TOLVAPTAN; EFFICACY; DEATH;
D O I
10.1097/MJT.0b013e3181e70a65
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to investigate the association between implantable cardioverter-defibrillator (ICD) status at the time of hospitalization for worsening heart failure (HF) with postdischarge events in patients with reduced left ventricular ejection fraction. We conducted an analysis of 4133 patients hospitalized for HF with left ventricular ejection fraction 40% or less in EVEREST. The final analysis included patients without an electrophysiological device (n = 3102) and those with an ICD (n = 600) at the time of enrollment. During a median follow-up of 300 days, all-cause mortality was 22.9% in the no device group and 35.2% in the ICD group (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.39-1.89). Rehospitalization for HF was 27.0% in the no device group and 46.8% in the ICD group (HR, 2.20; 95% CI, 1.92-2.52). After adjustment for multiple variables, the rates for all-cause mortality were similar (HR, 1.01; 95% CI, 0.83-1.22), but the ICD group had elevated rates of HF hospitalizations compared with the no device group (HR, 1.35; 95% CI, 1.14-1.60). In patients with reduced left ventricular ejection fraction, an ICD at presentation for hospitalization for worsening HF was associated with similar rates of death but higher rates of rehospitalization for HF. Given our findings, further studies should investigate optimization of care in patients already implanted with an ICD as well as the role of ICD implantation during or soon after hospitalization for HF in patients not yet implanted.
引用
收藏
页码:E78 / E87
页数:10
相关论文
共 21 条
  • [1] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 225 - 237
  • [2] Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
    Braunwald, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (19) : 1360 - 1369
  • [3] The pathophysiology of acute heart failure - Is it all about fluid accumulation?
    Cotter, Gad
    Felker, G. Michael
    Adams, Kirkwood F.
    Milo-Cotter, Olga
    O'Connor, Christopher M.
    [J]. AMERICAN HEART JOURNAL, 2008, 155 (01) : 9 - 18
  • [4] Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST)
    Gheorghiade, M
    Orlandi, C
    Burnett, JC
    Demets, D
    Grinfeld, L
    Maggioni, A
    Swedberg, K
    Udelson, JE
    Zannad, F
    Zimmer, C
    Konstam, MA
    [J]. JOURNAL OF CARDIAC FAILURE, 2005, 11 (04) : 260 - 269
  • [5] Acute heart failure syndromes -: Current state and framework for future research
    Gheorghiade, M
    Zannad, F
    Sopko, G
    Klein, L
    Piña, IL
    Konstam, MA
    Massie, BM
    Roland, E
    Targum, S
    Collins, SP
    Filippatos, G
    Tavazzi, L
    [J]. CIRCULATION, 2005, 112 (25) : 3958 - 3968
  • [6] Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials
    Gheorghiade, Mihai
    Konstam, Marvin A.
    Burnett, John C., Jr.
    Grinfeld, Liliana
    Maggioni, Aldo P.
    Swedberg, Karl
    Udelson, James E.
    Zannad, Faiez
    Cook, Thomas
    Ouyang, John
    Zimmer, Christopher
    Orlandi, Cesare
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12): : 1332 - 1343
  • [7] Acute Heart Failure Syndromes
    Gheorghiade, Mihai
    Pang, Peter S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (07) : 557 - 573
  • [8] Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure
    Hernandez, Adrian F.
    Fonarow, Gregg C.
    Hammill, Bradley G.
    Al-Khatib, Sana M.
    Yancy, Clyde W.
    O'Connor, Christopher M.
    Schulman, Kevin A.
    Peterson, Eric D.
    Curtis, Lesley H.
    [J]. CIRCULATION-HEART FAILURE, 2010, 3 (01) : 7 - 13
  • [9] Hjalmarson Å, 1999, LANCET, V353, P2001
  • [10] Rehospitalizations among Patients in the Medicare Fee-for-Service Program
    Jencks, Stephen F.
    Williams, Mark V.
    Coleman, Eric A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (14) : 1418 - 1428